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degradation time. No studies have been reported with
a bioabsorbable matrix and autologous cell seeding
for patch augmentation of the pulmonary artery. In
this study we tested a new, highly flexible, and rapid-
ly degrading polymer, poly-4-hydroxybutyrate (P-
4HB), seeded with autologous vascular cells to aug-
ment the main pulmonary artery in an ovine in vivo
model.
Biodegradable and absorbable material has beenbroadly used for reconstruction of the atrial wall,1
pericardium,2 and the right ventricular outflow tract.3
In surgery for congenital cardiac disease the ideal
material would be a nonthrombogenic living tissue
that would allow growth. The polymer used in the
above-mentioned studies, poly-3-hydroxybutyrate,
had the significant potential shortcoming of a long
Objective: In recent years bioabsorbable synthetic or biologic materials have
been used to augment the pulmonary artery or the right ventricular outflow
tract. However, each of these polymers has one or more shortcomings. None of
these patch materials has been seeded with cells. Thus, we have tested a fast-
absorbing biopolymer, poly-4-hydroxybutyric acid, with autologous cell seed-
ing for patch augmentation of the pulmonary artery in a juvenile sheep model.
Methods: Vascular cells were isolated from ovine peripheral veins (n = 6).
Bioabsorbable porous poly-4-hydroxybutyric acid patches (porosity > 95%)
were seeded on 3 consecutive days with a mixed vascular cell suspension
(21.3 ± 1.3 × 106 cells). Forty-five (± 2) days after the vessel harvest, 1
unseeded and 6 autologously seeded control patches were implanted into the
proximal pulmonary artery. The animals received no postoperative anticoag-
ulation. Follow-up was performed with echocardiography after 1 week and
before explantation after 1, 7, and 24 weeks (2 animals each) for the seeded
control patches and after 20 weeks for the nonseeded control patch.
Results: All animals survived the procedure. Postoperative echocardiography
of the seeded patches demonstrated a smooth surface without dilatation or
stenosis. Macroscopic appearance showed a smooth internal surface with
increasing tissue formation. Histology at 169 days demonstrated a near-com-
plete resorption of the polymer and formation of organized and functional
tissue. Biochemical assays revealed increasing cellular and extracellular
matrix contents. The control patch showed a slight bulging, indicating a
beginning dilatation. 
Conclusion: This experiment showed that poly-4-hydroxybutyric acid is a
feasible patch material in the pulmonary circulation.  (J Thorac Cardiovasc
Surg 2000;120:1158-68)
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Materials and methods
The general approach to cell isolation, culture, sorting, and
seeding was described in detail previously.4 Several modifi-
cations have been made in this study.
Cell isolation and culture. Segments of peripheral limb
vein (2-3 cm) were harvested from 6-week-old Dover lambs
(n = 6). The vessels were minced into 1-mm2 pieces and cul-
tured in high-glucose Dulbecco’s modified Eagle’s medium
(Gibco BRL; Life Technologies Inc, Rockville, Md) supple-
mented with 10% fetal bovine serum (Sigma Chemical
Company, St Louis, Mo), 1% L-glutamine, penicillin, and
streptomycin (Sigma) on P100 dishes (Corning Inc, Corning,
NY). After migration of cells onto the dishes (7-10 days after
the harvest), the cells were serially passaged on 1% collagen-
precoated tissue culture ware (Corning Inc). Approximately
37 ± 2 additional days were needed to obtain 12 confluent
T75 tissue culture flasks. Representative cell samples were
labeled with an acetylated low-density lipoprotein (LDL)
marker (Biomedical Technologies Inc, Stoughton, Mass) that
is selectively taken up by endothelial cells through the scav-
enger pathway. After 24 hours’ incubation, the cell popula-
tions were analyzed by use of a fluorescence-activated cell
sorter to determine the ratio of LDL-positive (endothelial
cells) and LDL-negative cells (smooth muscle or fibroblasts).
The analysis revealed a ratio of 5% ± 1% LDL-positive
(endothelial cells) and 85% ± 1% LDL-negative cells
(smooth muscle cells or fibroblasts). The remaining 10%
could not be clearly classified in one of the two populations.
Bioabsorbable polymer.  The P-4HB (PHA4400) was pro-
vided by Tepha, Inc (Cambridge, Mass). The size of the patch
was 10 × 25 mm, with a thickness of 1.6 mm (Fig 1, A). A
combination of salt-leaching technique5 and solvent evapora-
tion6 was used to create a highly porous material (porosity
>95%, pore sizes of 180-240 µm; Fig 1, B). In a recent study
with 3 different subcutaneously (rat) implanted PHA 4400
discs (film, 50% or 80% porosity), we evaluated an in vivo
degradation time between 20 weeks for the polymer with
80% porosity and 56 weeks for the film (Stock and associ-
ates, 1999, unpublished results). The patches were sterilized
with cold ethylene oxide.
Cell seeding. Before cell seeding, the patches were pre-
coated with 0.1 mg/mL collagen type I (Vitrogen 100;
Cohesion Inc, Westford, Mass) for 24 hours to improve cell-
polymer attachment. After 37 ± 2 days in cell culture, mixed
vascular cells (endothelial cells, smooth muscle cells, and
fibroblasts; 21.3 ± 1.3 × 106 cells each time) were dripped
onto the inside of the patch (seeding time, 10 minutes) on 3
consecutive days. The patches were cultured in high-glucose
Dulbecco’s modified Eagle’s medium (GIBCO, BRL) sup-
plemented with 10% fetal bovine serum (Sigma), 1% L-glu-
tamine, penicillin, and streptomycin (Sigma) in tissue culture
plastic ware (Corning Inc).
After 1 final incubation day in culture media, the constructs
were implanted.
Implantation. At 45 ± 2 days after the initial cell harvest,
the same 6 animals from which the initial vessel was harvest-
ed (average weight, 25 ± 5 kg) underwent augmentation of
the pulmonary artery with an autologous tissue-engineered
patch. In one other animal an acellular patch was implanted
(control patch with the same precoating and culture condi-
tions before implantation but no cell seeding). Anesthesia
was induced with a 2-mg/kg dose of ketamine, a 0.02-mg/kg
Fig 1. A, Polymer scaffold (P-4HB) 10 × 25 mm with a thickness of 1.6 mm. B, Surface electron microscopy of
highly porous (porosity >95%) P-4HB (PHA4400). (Original magnification 500×.)
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dose of atropine, and an intravenous bolus infusion of 2
mg/kg of propofol. Anesthesia was maintained with inhala-
tional isoflurane. Before skin incision, an intercostal nerve
block with 0.25% bupivacaine hydrochloride (INN: bupiva-
caine) was administered. The heart was exposed by means of
a left anterolateral thoracotomy entering the chest through the
fourth intercostal space. By means an atraumatic vascular
Cooley-Derra clamp, the proximal pulmonary artery above
the valvular level was clamped tangentially as far down as
tolerated by the animal. A segment of the pulmonary artery
Fig 2. Implanted patch in the main pulmonary artery.
Fig 3. Echocardiographic assessment. A, Long axis after 1 week of implantation. Enhanced echocardiographic den-
sity of patch material. B, Long axis after 26 weeks of implantation. Patch area is undistinguishable from native pul-
monary artery.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 6
Evolving technology 1161
Fig 4. A, Gross appearance of seeded tissue-engineered patch 26 weeks in vivo (outside). B, Gross appearance of seeded
tissue-engineered patch 26 weeks in vivo (inside). C, Gross appearance of nonseeded tissue-engineered patch 20 weeks in
vivo (view into the proximal pulmonary artery). 
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(1.5 × 3 cm) was excised, and the defect was replaced with
the patch using running 5-0 polydioxanone sutures (Ethicon,
Inc, Somerville, NJ; Fig 2).
The thoracic wall was closed in layers with resorbable
sutures. No postoperative anticoagulation was given. All
animals received 1000 mg of cefazolin (Apothecon) for the
first postoperative week on a daily basis. For pain control,
intramuscular buprenorphine injections were administered
for the first 3 days and further on demand. All animals
received humane care in compliance with the “Guide for
the Care and Use of Laboratory Animals” published by the
National Institutes of Health (National Institutes of Health
publication No. 85-23, revised 1985). After 7 days in
Children’s Hospital research facilities, the animals were
moved to an offsite indoor housing facility.
Evaluation of the engineered patches and adjacent
native pulmonary artery. After implantation, Doppler
echocardiography with either an Accuson 128 or Hewlett-
Packard Sonos 1500 Cardiac Imager (Hewlett-Packard,
Andover, Mass) equipped with a 7- to 7.5-MHz phased-
arrayed transducer was used periodically to evaluate the
patch area. Two-dimensional Doppler echocardiographic
examination was performed on the main pulmonary artery 1
week after implantation and immediately before euthanasia
after 1, 7, and 25 weeks for the seeded and 20 weeks for the
unseeded patches. Evaluations included imaging of the pul-
monary artery from a long- and short-axis view.
The explanted patch and the adjacent native pulmonary artery
were evaluated macroscopically and histologically. Histology
consisted of a hematoxylin and eosin stain for gross morpholo-
gy, a Movat pentachrome stain for extracellular matrix compo-
nents, and immunohistochemical staining with human von
Willebrand factor for the identification of endothelial cells.
For quantification of cellular and extracellular components,
histochemical assays were performed. DNA content was mea-
sured with a commercially available cell proliferation assay
kit (CyQuant; Molecular Probes, Inc, Eugene, Ore) after prior
proteinase K digestion.7 For determination of collagen con-
tent, tissue 4-hydroxyproline levels were determined.8 Elastin
was quantified after tissue extraction by means of 0.1% hot
oxalic acid7 with a FASTIN elastin assay (Biocolor Ltd,
Belfast, Northern Ireland), and proteoglycan-glycosaminogly-
can content was quantified after tissue extraction by means of
guanidine HCl9 with a BLYSCAN proteoglycan/glycos-
aminoglycan assay (Biocolor Ltd). For measurement of
matrix turnover and remodeling, metalloproteinases (MMPs)
and tissue inhibitors of MMPs (TIMPs) were extracted from
tissue samples by use of 2 mol/L NaCl and 10 mmol/L tris-
hydroxymethylaminomethane (TRIS).10 MMP presence and
activity were determined by a substrate gel electrophoresis
Fig 5. A, Histology of seeded patch (169 days in vivo), with stain highlighting extracellular matrix elements and
showing presence of collagen (yellow) and proteoglycans (green). Asterisk indicates remaining polymer material.
B, Seeded patch material (after 169 days in vivo) showing organized tissue formation with flattened cells on the
luminal surface resembling endothelial cells (arrows). C, Immunohistochemical stain with human von Willebrand
factor identifying endothelial cell lining of the luminal surface of the seeded patch. (A, Movat pentachrome stain,
original magnification 40×; B, hematoxylin and eosin stain, original magnification 40×; C, von Willebrand factor,
original magnification 100×.)
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(zymography) with a sodium dodecylsulfate–polyacrylamide
gel copolymerized with gelatin according to the method of
Peters and associates.11 MMP inhibitory activity (TIMP activ-
ity) was determined by the addition of bovine corneal collage-
nase to an appropriately diluted sample in wells containing
carbon 14–radiolabeled collagen. For protein determination,
protein was extracted by means of 2 mol/L NaCl and 10
mmol/L TRIS.10 Extracted protein content was determined
with a Bio-Rad protein assay kit (Bio-Rad Laboratories,
Hercules, Calif) according to the manufacturer’s specifica-
tions, with bovine serum albumin as the standard.
All extracellular matrix components and active enzymes
(MMPs and TIMPs) were normalized against protein concen-
tration.
Results
All animals survived the operative procedure. During
patch implantation (seeded and nonseeded patches), no
bleeding occurred from the suture line, highlighting the
compliance and elasticity of the polymer. Doppler
echocardiography of the seeded patches revealed no
signs of thrombus formation, stenosis, or dilatation.
During the first echocardiographic examination (1 week
after the operation), the patch material was clearly iden-
tified by a higher echocardiographic density (Fig 3, A).
After 26 weeks, the patch became indistinguishable
from the surrounding native pulmonary artery (Fig 3, B).
Because of technical problems during induction of
anesthesia, the control animal died before the echocar-
diogram at 20 weeks.
Macroscopic evaluation of the seeded patches
showed, after 7 weeks, an opaque, smooth, internal
surface with evidence of tissue formation and neo-
vascularization on the outside (Fig 4, A and B). The
nonseeded control patch demonstrated a distinct
bulging, indicating the beginning of aneurysm forma-
tion (Fig 4, C).
The histology at 24 weeks showed organized fibrous
tissue with flattened cells resembling endothelial cells.
Fig 6. Content of seeded patch, unseeded patch, and native pulmonary artery. A, DNA; B, 4-hydroxyproline 
(4-OHP; collagen).
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Deep below the surface, remnants of the patch materi-
al were found surrounded by fibrous tissue. The
remains of the polymer had a moderate and sharply
demarcated mononuclear and focal giant cell reaction,
which was exclusively limited to the polymer itself
without affecting the surrounding tissue (Fig 5, A). A
Movat-pentachrome stain revealed large amounts of
proteoglycans and collagen (Fig 5, B). The immuno-
histochemical stain with human von Willebrand factor
confirmed the presence of endothelial cells on the
internal surface of both the seeded and unseeded patch-
es (Fig 5, C).
The biochemical assays for the quantification of cel-
lular and extracellular matrix components revealed the
following results. DNA content in the seeded patch
increased over the observed time to a maximum at 49
days with 91% of the native pulmonary artery, followed
by a decrease toward 169 days (Fig 6, A). Collagen,
measured as content of 4-hydroxyproline, showed a
similar pattern with a maximum at 49 days (Fig 6, B).
Proteoglycans and glycosaminoglycans expressed the
same time course, with a high at 49 days and decreased
levels at 169 days (Fig 6, C). Finally, elastin content
exceeded that of the native pulmonary artery, with
150% at 49 days, but decreased toward 169 days (Fig
6, D). The unseeded patch evaluated at 149 days in vivo
showed amounts of DNA, 4-hydroxyproline, proteo-
glycans-glycosaminoglycans, and elastin equivalent to
that of the native pulmonary artery.
The determination of the MMPs, especially MMP-2
(Gelatinase A, the MMP that degrades basement mem-
brane collagen) showed a maximal activity at 49 days
in the seeded patches. Measurements at 169 days
revealed no differences in the activity between the tis-
sue-engineered patch and the native pulmonary artery
(Fig 7). In seeded patches the levels of TIMPs reached
maximal inhibitory activity at 49 days, with a decrease
to undetectable levels at 169 days. The unseeded con-
Fig 6. Cont’d. C, Proteoglycans-glycosaminoglycans; D, elastin. TE, Tissue-engineered patch.
C
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trol patch showed significant MMP-2 activity but no
inhibitory activity of TIMPs at 140 days after implan-
tation (Fig 8).
Discussion
Patch augmentation of the hypoplastic or stenotic
right ventricular outflow tract or pulmonary artery
system is a common procedure for congenital cardiac
defects, such as tetralogy of Fallot. The use of non-
degradable materials, such as polytetrafluoroethylene,
has been associated with few complications. However,
we believe that a viable vascular tissue substitute with
the ability to regenerate, remodel, and grow has sub-
stantial advantages over nonvital materials. Bio-
absorbable materials for the augmentation of the right
ventricular outflow tract and pulmonary artery have
been investigated in the past.3 Poly-3-hydroxybutyrate
was used in these studies, but it differs significantly
from the P-4HB used in the present study because of
a longer degradation time (>12 months to ~6 months)
and a different fabrication (fiber-based configuration
vs foam). In addition, it was not seeded with cells
before implantation. Malm and colleagues3 described
formation of a neointima and neomedia, which was
comparable with that found in the native pulmonary
artery. In this study we seeded 6 patches with autolo-
gous vascular cells and implanted one further non-
seeded patch into the pulmonary circulation. After
140 days in vivo, this control patch showed a bulging,
potentially indicating the beginning of aneurysm for-
mation. In contrast, Malm and associates did not
observe any aneurysm formation in their study. These
conflicting observations raise the question of whether
seeding of biodegradable patch material is necessary,
depending on the degradation time and polymer con-
figuration.
Fig 7. Substrate gel zymography of tissue samples collected from native (A) and tissue-engineered (B) pulmonary
artery before implantation and at different time points up to 169 days. MMP activities are observed as zones of clear-
ance in a polyacrylamide gel impregnated with gelatin and stained with Coomassie R-250; each band represents one
animal. A band of proteolytic activity was observed at an apparent relative molecular mass (Mr) of 62 to 66 kd and cor-
responds to the active form of MMP-2. A second band at an apparent relative molecular mass of 56 to 60 kd corre-
sponds to an autoactivated isoform of the active MMP-2. Another proteolytic band at an apparent relative molecular
mass of 72 to 76 kd corresponds to the latent form of MMP-2. C, Control patch without cell seeding.
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We did observe an ingrowth of tissue from the sur-
rounding native pulmonary artery onto the nonseeded
control patch with quantitative amounts of cellular and
extracellular components similar to the native pul-
monary artery. Malm and associates3 made qualitatively
similar observations. Huynh and colleagues12 recently
described the concept of an acellular collagen graft
(internal diameter, 4 mm) as a small-diameter vascular
substitute. After implantation in a rabbit arterial bypass
model (carotid artery), they observed a homogenous tis-
sue ingrowth from both distal and proximal anastomosis
and reported patency for up to 3 months. Autologous
reseeding of large surfaces areas, such as a vascular
prosthesis (Dacron), from the adjacent native tissue is a
phenomenon seen regularly in animals but seems to
occur only to a limited extent in human subjects.13 It
remains highly speculative whether the observed autol-
ogous repopulation of acellular and unseeded matrices,
as observed in our studies and in those of Malm,3
Huynh,12 and their colleagues, can be transferred to
human subjects. The unseeded patch did show quantita-
tive amounts of cellular and extracellular components
resembling the native pulmonary artery, but the bulging
of the patch and the increased activity of matrix
enzymes (MMPs) may indicate a disturbed remodeling
process. Therefore, if some seeding becomes unavoid-
able, two critical questions arise. The first question con-
cerns the source of cells, and the second question is
whether the cellular components of the seeded patches
are derived from the cells that were seeded onto the
patch or originate from the surrounding pulmonary
artery. In this study we harvested segments of peripher-
al limb veins corresponding to the human saphenous
vein for cell isolation. In prior experiments, we used sec-
tions of carotid arteries. We believe that the use of
venous segments in combination with proper cell culture
techniques minimizes the risk of jeopardizing the origi-
nally supplied tissue. New research with mesenchymal
stem cells14 and circulating bone marrow–derived
endothelial cells15 may represent an additional source of
cells with thus far unknown potential.
To differentiate whether the cellular components of
the seeded patches are derived from the cells that were
harvested and seeded onto the patch or originate from
the surrounding pulmonary artery, our group has previ-
ously used fluorescent carbocyanine dyes16 for cell
labeling before seeding.17 It was possible to identify
these labeled cells for up to 6 weeks after implantation.
However, successful longer term labeling and tracing
without adverse effects, such as cell toxicity, remains
an unsolved problem. All currently available immuno-
fluorescent dyes are passed on during cell division to
each daughter generation with equal amounts, resulting
in an ongoing dye dilution. Accordingly, the longest
observed follow-up of immunofluorescent dyed
endothelial cells in vivo is 60 days.18 Retroviral or ade-
noviral transfection of cells with a green fluorescent
protein may eliminate this dilution problem and might
offer an attractive pathway for long-term observa-
tions.19,20 We are currently investigating the potential
use of this technique for long-term labeling of vascular
smooth muscle cells and endothelial cells.
In this study we observed an initial increase in tissue
formation, with maximum deposition of cells and
Fig 8. Activity of TIMPs.
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extracellular matrix components and a maximum activ-
ity of tissue remodeling enzymes at 49 days. Samples
from later time points showed a decrease of all compo-
nents until the end point of the study after 169 days. It
is unclear whether a decrease in DNA is due to cell
death or greater amounts of protein in the tissue. Cell
death has several potential causes. Toxicity of the poly-
mer has been recently investigated in our group and
revealed no differences among glass, Pyrex, and P-4HB
(Stock and associates, 1999, unpublished results).
Ischemia and cell death caused by insufficient nutri-
tional support is one potential explanation for
decreased cell count over the observed time period. The
histology clearly showed ingrowth of blood vessels into
the polymer, but suboptimal nutritional supply cannot
be ruled out as a potential explanation for the decreased
cellular content in the tissue-engineered patches. A sec-
ond explanation for the cell loss is the well-known
characterized mechanism of programmed cell death or
apoptosis.21,22 We are currently investigating how
apoptosis may affect our tissue-engineered constructs.
Conclusion
In this feasibility study we have fabricated a viable
vascular patch material that is able to function for up to
6 months in the pulmonary artery circulation. The one
unseeded patch developed a significant bulging.
Further work is needed to study the long-term outcome
and growth ability of the patches. Advances in cell biol-
ogy might offer the potential for avoidance of a vessel
harvest by use of circulating pluripotential stem cells,
and we are optimistic that the creation of viable tissue-
engineered patches will become applicable for clinical
use.
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